应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00460 四环医药
交易中 09-20 13:12:03
0.540
+0.000
0.00%
最高
0.550
最低
0.530
成交量
250.80万
今开
0.540
昨收
0.540
日振幅
3.70%
总市值
50.33亿
流通市值
50.33亿
总股本
93.20亿
成交额
135.52万
换手率
0.03%
流通股本
93.20亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
四环医药盘中异动 早盘快速上涨5.88%报0.540港元
市场透视 · 09-13
四环医药盘中异动 早盘快速上涨5.88%报0.540港元
四环医药(00460)股价上升5.882%,现价港币$0.54
阿斯达克财经 · 09-13
四环医药(00460)股价上升5.882%,现价港币$0.54
南向资金9月12日净卖出四环医药271.10万股 连续3日减持
市场透视 · 09-13
南向资金9月12日净卖出四环医药271.10万股 连续3日减持
四环医药(00460)下跌5.45%,报0.52元/股
金融界 · 09-09
四环医药(00460)下跌5.45%,报0.52元/股
南向资金9月5日净卖出四环医药103.80万股 连续3日减持
市场透视 · 09-09
南向资金9月5日净卖出四环医药103.80万股 连续3日减持
医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损
新浪证券 · 09-06
医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损
四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长
格隆汇 · 09-05
四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长
四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%
新浪港股 · 08-30
四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%
【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙
金吾资讯 · 08-30
【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙
四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可
智通财经网 · 08-30
四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可
四环医药(00460.HK):附属减重药物临床试验申请获批
阿斯达克财经 · 08-30
四环医药(00460.HK):附属减重药物临床试验申请获批
四环医药(00460):惠升生物开发的司美格鲁肽注射液减重适应症IND申请获国家药监局批准
智通财经 · 08-30
四环医药(00460):惠升生物开发的司美格鲁肽注射液减重适应症IND申请获国家药监局批准
四环医药(00460)将于10月10日派发中期股息每股0.019元
智通财经网 · 08-30
四环医药(00460)将于10月10日派发中期股息每股0.019元
【四环医药:司美格鲁肽注射液减重适应症IND申请获批】金十数据8月30日讯,四环医药公告,本集团旗下非全资附属公司惠升生物开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获中国国家药监局批准。
美港电讯 · 08-30
【四环医药:司美格鲁肽注射液减重适应症IND申请获批】金十数据8月30日讯,四环医药公告,本集团旗下非全资附属公司惠升生物开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获中国国家药监局批准。
《业绩》四环医药(00460.HK)半年亏损收窄至3,342.4万元人民币 派中期息1.9分人民币
阿斯达克财经 · 08-30
《业绩》四环医药(00460.HK)半年亏损收窄至3,342.4万元人民币 派中期息1.9分人民币
四环医药08月28日主力资金流出37万元 连续3日减仓
市场透视 · 08-28
四环医药08月28日主力资金流出37万元 连续3日减仓
四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩
格隆汇资讯 · 08-20
四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩
四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万
阿斯达克财经 · 08-20
四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万
四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图
格隆汇资讯 · 08-19
四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
金吾财讯 · 08-16
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
加载更多
公司概况
公司名称:
四环医药
所属市场:
SEHK
上市日期:
--
主营业务:
四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。
发行价格:
--
{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.54,"timestamp":1726808860759,"preClose":0.54,"halted":0,"volume":2508000,"delay":0,"floatShares":9319999206,"shares":9319999206,"eps":-0.0064229295,"marketStatus":"交易中","marketStatusCode":2,"change":0,"latestTime":"09-20 13:12:03","open":0.54,"high":0.55,"low":0.53,"amount":1355150,"amplitude":0.037037,"askPrice":0.54,"askSize":775000,"bidPrice":0.53,"bidSize":3402000,"shortable":3,"etf":0,"ttmEps":-0.004522582574488803,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1726819800000},"adr":0,"adjPreClose":0.54,"dividendRate":0.038778,"openAndCloseTimeList":[[1726795800000,1726804800000],[1726808400000,1726819200000]],"volumeRatio":1.273078,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2467967761","title":"四环医药盘中异动 早盘快速上涨5.88%报0.540港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467967761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467967761?lang=zh_cn&edition=full","pubTime":"2024-09-13 10:24","pubTimestamp":1726194285,"startTime":"0","endTime":"0","summary":"2024年09月13日早盘10时24分,四环医药股票出现异动,股价急速拉升5.88%。截至发稿,该股报0.540港元/股,成交量634.3万股,换手率0.07%,振幅5.88%。资金方面,该股资金流入329.965万港元,流出2.056万港元。四环医药股票所在的药品行业中,整体涨幅为0.36%。其相关个股中,联康生物科技集团、四环医药、凯莱英涨幅较大,振幅较大的相关个股有联康生物科技集团、君圣泰医药-B、顺腾国际控股,振幅分别为10.29%、8.79%、8.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409131024459719b351&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409131024459719b351&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2467858764","title":"四环医药(00460)股价上升5.882%,现价港币$0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2467858764","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467858764?lang=zh_cn&edition=full","pubTime":"2024-09-13 10:24","pubTimestamp":1726194240,"startTime":"0","endTime":"0","summary":"[上升股]四环医药(00460) 股价在上午10:24比前收市价上升5.882%,现股价为港币$0.54。至目前为止,今日最高价为$0.54,而最低价为$0.51。总成交量为634.3万股,总成交金额为港币$332.021万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2409132089/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","00460","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2467655017","title":"南向资金9月12日净卖出四环医药271.10万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2467655017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467655017?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:30","pubTimestamp":1726191006,"startTime":"0","endTime":"0","summary":"9月12日,南向资金减持四环医药271.10万股连续3日减持。截止当日收盘,港股通共持有四环医药81023.40万股,占流通股8.68%。四环医药近5个交易日下跌7.27%,港股通累计减持626.90万股;近20个交易日下跌3.77%,港股通累计减持1395.40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130930369ef92c99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409130930369ef92c99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1600","BK1191","00460","BK1515"],"gpt_icon":0},{"id":"2466136663","title":"四环医药(00460)下跌5.45%,报0.52元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466136663","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466136663?lang=zh_cn&edition=full","pubTime":"2024-09-09 14:07","pubTimestamp":1725862075,"startTime":"0","endTime":"0","summary":"9月9日,四环医药(00460)盘中下跌5.45%,截至14:07,报0.52元/股,成交483.67万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2024年中报,四环医药营业总收入9.5亿元、净利润-3342.4万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/09140743112765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1593","BK1191","00460","BK1600"],"gpt_icon":0},{"id":"2466690436","title":"南向资金9月5日净卖出四环医药103.80万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2466690436","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466690436?lang=zh_cn&edition=full","pubTime":"2024-09-09 09:30","pubTimestamp":1725845408,"startTime":"0","endTime":"0","summary":"9月5日,南向资金减持四环医药103.80万股连续3日减持。截止当日收盘,港股通共持有四环医药81546.50万股,占流通股8.73%。四环医药近5个交易日上涨3.77%,港股通累计减持431.20万股;近20个交易日上涨1.85%,港股通累计减持914.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409090930319eed1a9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409090930319eed1a9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1593","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2465966587","title":"医美产业链上游半年报|爱美客增长失速、华熙生物业绩双降垫底医美三剑客 四环医药延续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2465966587","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465966587?lang=zh_cn&edition=full","pubTime":"2024-09-06 17:07","pubTimestamp":1725613629,"startTime":"0","endTime":"0","summary":"在医美产业链上游上市公司业绩披露中,仅有爱美客、昊海生科、华东医药营收净利润双增,江苏吴中增收不增利、华熙生物业绩双降、四环医药营收下滑且延续亏损。相较以往,爱美客业绩增速显著放缓。或是受业绩增速大幅下降影响,爱美客半年报发布次日,股价跌幅超12%。2024年上半年,华熙生物业绩双降,共实现营收28.1亿元,同比下降了8.61%;实现净利润3.42亿元,同比下降了19.51%,同时公司销售净利率进一步下降至12.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409061707189ee5468f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409061707189ee5468f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","00460","BK1515","BK1600"],"gpt_icon":0},{"id":"2465519803","title":"四环医药(0460.HK):医美业务收入大增66.4%,转型显效开启加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2465519803","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465519803?lang=zh_cn&edition=full","pubTime":"2024-09-05 15:15","pubTimestamp":1725520508,"startTime":"0","endTime":"0","summary":"医美转型兑现落地,医美业务收入大增66.4%","market":"sg","thumbnail":"https://img7.gelonghui.com/column/4.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1007633","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1600","BK1515","BK1593","BK1191","00460"],"gpt_icon":0},{"id":"2463736302","title":"四环医药发布中期业绩 医美产品的收益约3.23亿元同比上升约66.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463736302","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463736302?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:54","pubTimestamp":1724993684,"startTime":"0","endTime":"0","summary":"四环医药发布截至2024年6月30日止6个月业绩,该集团期内取得收益9.5亿元;公司拥有人应占亏损3342.4万元;每股基本亏损0.36分;拟派发中期股息每股1.9分。 来自创新药及其他药品的收益约为2960万元,同比上升了约85.0%,主要由于轩竹生物科技股份有限公司自研的一类新药安奈拉唑钠于2023年下半年获批上市并开始产生收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-30/doc-incmkytp9119889.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-30/doc-incmkytp9119889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1600","BK1515","BK1593","BK1191","00460"],"gpt_icon":0},{"id":"2463278321","title":"【港股通】四环医药(00460)中期亏损收窄32.67% 派中期股息2.1港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2463278321","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463278321?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:26","pubTimestamp":1724991997,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药 公布,截至2024年6月30日止六个月,公司拥有人应占亏损3342.4万元,同比亏损收窄32.67%,每股基本亏损0.36分。派中期股息每股1.9分。其中来自医美产品的收益约3.23亿元,同比上升约66.4%;来自仿制药的收益约5.97亿元,同比下降约29.4%;来自创新药及其他药品的收益约2960万元,同比上升约85.0%。期内,集团毛利6.09亿元,同比减少18.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301227159f67a22b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","BK1600","HSCEI","BK1191","BK1515","07226","00460","BK1593"],"gpt_icon":0},{"id":"2463222087","title":"四环医药(00460)发布中期业绩 医美产品的收益约3.23亿元 同比上升约66.4% 美颜空间产品获得市场的高度认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2463222087","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463222087?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:12","pubTimestamp":1724991143,"startTime":"0","endTime":"0","summary":"公告称,来自医美产品的收益约为3.23亿元,同比上升约66.4%,主要由于期内集团旗下医美平台美颜空间加大与多家医美机构的战略合作以及大力推广营销战略3.0版本升级取得阶段性的成功,产品获得市场的高度认可,从而推动医美销售收入大幅增长。目前医美平台美颜空间已有20余款产品获批上市,其中包括5款产品已上市销售,另外有40余款产品处于报产审批或在研阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301215259f679b36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408301215259f679b36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","00460","BK1515","BK1600"],"gpt_icon":0},{"id":"2463622013","title":"四环医药(00460.HK):附属减重药物临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2463622013","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463622013?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:12","pubTimestamp":1724991120,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准,这是该产品继成人2型糖尿病患者的血糖控制适应症后,获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1600","BK1141","BK1576","BK1191","BK1515","00460","BK1583","BK1593"],"gpt_icon":0},{"id":"2463270202","title":"四环医药(00460):惠升生物开发的司美格鲁肽注射液减重适应症IND申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2463270202","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463270202?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:11","pubTimestamp":1724991106,"startTime":"0","endTime":"0","summary":"智通财经APP讯,四环医药 发布公告,集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获中华人民共和国国家药品监督管理局批准,这是该产品继成人2型糖尿病患者的血糖控制适应症后,获得临床试验批准的第二个适应症。司美格鲁肽注射液是目前减重领域的最大单品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1176175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK1593","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2463227493","title":"四环医药(00460)将于10月10日派发中期股息每股0.019元","url":"https://stock-news.laohu8.com/highlight/detail?id=2463227493","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463227493?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:07","pubTimestamp":1724990857,"startTime":"0","endTime":"0","summary":"智通财经APP讯,四环医药(00460)发布公告,该公司将于2024年10月10日派发中期股息每股0.019元。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1176172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1593","BK1600","BK1191","BK1515","00460"],"gpt_icon":0},{"id":"2463126227","title":"【四环医药:司美格鲁肽注射液减重适应症IND申请获批】金十数据8月30日讯,四环医药公告,本集团旗下非全资附属公司惠升生物开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获中国国家药监局批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2463126227","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463126227?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:07","pubTimestamp":1724990843,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","03347","BK1593","BK1576","BK1600","00460","BK1583","BK1191","BK1141"],"gpt_icon":0},{"id":"2463227091","title":"《业绩》四环医药(00460.HK)半年亏损收窄至3,342.4万元人民币 派中期息1.9分人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2463227091","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463227091?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:03","pubTimestamp":1724990580,"startTime":"0","endTime":"0","summary":"四环医药公布截至今年6月底止中期业绩,收益9.5亿元人民币(下同),按年跌10%。亏损收窄至3,342.4万元,上年同期蚀4,964.4万元;每股亏损0.36分。(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)过往派息公布日期派息事项派息内容2024/03/28末期业绩无派息2023/08/29中期业绩无派息2023/03/24末期业绩普通股息:人民币 0.0320﹙相当于港元 0.0370﹚2022/08/30中期业绩普通股息:人民币 0.0010﹙相当于港元 0.0010﹚AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377597/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00460","BK1593","BK1600","BK1515","BK1191"],"gpt_icon":0},{"id":"2462248055","title":"四环医药08月28日主力资金流出37万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2462248055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462248055?lang=zh_cn&edition=full","pubTime":"2024-08-28 16:15","pubTimestamp":1724832918,"startTime":"0","endTime":"0","summary":"08月28日,四环医药股价收平报0.53元,成交金额210万元,换手率0.04%,振幅1.89%,量比1.17。四环医药今日主力资金净流出37万元,连续3日净流出,上一交易日主力净流出49万元,今日环比减少24.49%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为52.94%,平均跌幅为2.20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082816152895cb9493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082816152895cb9493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2460022438","title":"四环医药(00460.HK)将于8月30日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2460022438","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460022438?lang=zh_cn&edition=full","pubTime":"2024-08-20 17:01","pubTimestamp":1724144487,"startTime":"0","endTime":"0","summary":"格隆汇8月20日丨四环医药(00460.HK)公布,公司将于2024年8月30日举行董事会会议,藉以考虑及批准公司及其附属公司截至2024年6月30日止六个月中期业绩及其发布,并考虑派付中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201701379f3d4a6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201701379f3d4a6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1600","BK1191","00460","BK1515"],"gpt_icon":0},{"id":"2460019587","title":"四环医药(00460)出现大手买入290万股,成交价$0.54,涉资156.6万","url":"https://stock-news.laohu8.com/highlight/detail?id=2460019587","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460019587?lang=zh_cn&edition=full","pubTime":"2024-08-20 10:13","pubTimestamp":1724119980,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在上午10:13出现大手买入,成交量为290万,成交价为港币$0.54,涉资156.6万。至目前为止,股价跌1.852%,今日最高价为$0.54,而最低价为$0.53,总成交量为362.5万股,总成交金额港币$195.659万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2408203471/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1600","BK1191","00460","BK1515"],"gpt_icon":0},{"id":"2460725708","title":"四环医药(00460.HK):进击的惠升生物:两大国产首款胰岛素力作!重塑糖尿病治疗版图","url":"https://stock-news.laohu8.com/highlight/detail?id=2460725708","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460725708?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:45","pubTimestamp":1724028329,"startTime":"0","endTime":"0","summary":"在不到十天的时间里,两款“国产首个”胰岛素的获批上市,可以说重塑了国内胰岛素的市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081908454195a496e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081908454195a496e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","00460","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2459250009","title":"医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强","url":"https://stock-news.laohu8.com/highlight/detail?id=2459250009","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459250009?lang=zh_cn&edition=full","pubTime":"2024-08-16 14:26","pubTimestamp":1723789603,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股全线上扬,康哲药业(00867)涨9.47%,现代牙科(03600)涨4.93%,四环医药(00460)涨3.85%,医思健康(02138)涨2.86%,复星医药(02196)涨2.6%,瑞尔集团(06639)涨2.27%,昊海生物科技(06826)涨1.95%。开源证券研报指出,建议关注医美、化妆品行业的投资机会。医美类差异化上游厂商抢占市场能力更强,长期看“渗透率+国产化率+合规化程度”多维提升逻辑未变;化妆品行业温和复苏,机会与挑战并存,把握渠道、成分、品类等细分结构性机会且综合竞争力强劲的国货美妆品牌有望在变化中抢占市场。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942461","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1215","02138","LU2488822045.USD","03600","SG9999015952.SGD","00867","06826","02196","SG9999015978.USD","BK1100","BK1219","BK1191","BK1583","BK1161","06639","SG9999004220.SGD","SG9999015945.SGD","BK1515","BK1593","BK1600","BK1511","SG9999015986.USD","00460"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0588},{"period":"1month","weight":0.0189},{"period":"3month","weight":-0.0182},{"period":"6month","weight":-0.0526},{"period":"1year","weight":-0.1562},{"period":"ytd","weight":-0.1692}],"compareEarnings":[{"period":"1week","weight":0.0448},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0917},{"period":"1year","weight":0.0071},{"period":"ytd","weight":0.0567}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.124332},{"month":2,"riseRate":0.571429,"avgChangeRate":0.002088},{"month":3,"riseRate":0.357143,"avgChangeRate":-0.025475},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029528},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.005604},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.006553},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.00596},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.024328},{"month":9,"riseRate":0.076923,"avgChangeRate":-0.076175},{"month":10,"riseRate":0.583333,"avgChangeRate":0.030986},{"month":11,"riseRate":0.538462,"avgChangeRate":0.020616},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.01024}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}